Biocryst Pharmaceuticals (BCRX) Cash & Equivalents (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Cash & Equivalents of $854000.0 for Q1 2026, up 324.88% on a QoQ basis from $201000.0 in Q4 2025, and up 193.47% year-over-year from $291000.0 in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Cash & Equivalents (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $854000.0 for Q1 2026.
- Quarterly Cash & Equivalents rose 193.47% year-over-year to $854000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $854000.0 (up 193.47% YoY) and the FY2025 annual result came in at $201000.0, down 99.81% from the prior year.
- Cash & Equivalents was $854000.0 for Q1 2026 at Biocryst Pharmaceuticals, up from $201000.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $395.5 million in Q1 2022 and bottomed at $201000.0 in Q4 2025.
- A 5-year average of $91.2 million and a median of $84.1 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents surged 9767.86% — and 2025, when it sank 99.81%.
- Biocryst Pharmaceuticals' Cash & Equivalents stood at $1.5 million in 2022, then surged by 7416.51% to $110.6 million in 2023, then declined by 5.36% to $104.7 million in 2024, then sank by 99.81% to $201000.0 in 2025, then surged by 324.88% to $854000.0 in 2026.
- Business Quant data shows BCRX's Cash & Equivalents at $854000.0 in Q1 2026, $201000.0 in Q4 2025, and $84.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | 854,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 854,000.00 |
| Dec 31, 2025 | 201,000.00 |
| Sep 30, 2025 | 84.08 Mn |
| Jun 30, 2025 | 492,000.00 |
| Mar 31, 2025 | 291,000.00 |
| Dec 31, 2024 | 104.71 Mn |
| Sep 30, 2024 | 96.84 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 84.33 Mn |
| Dec 31, 2023 | 110.64 Mn |
| Sep 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | 146.22 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.47 Mn |
| Sep 30, 2022 | 246.90 Mn |
| Jun 30, 2022 | 272.57 Mn |
| Mar 31, 2022 | 395.50 Mn |
| Dec 31, 2021 | 504.39 Mn |
| Sep 30, 2021 | 199.60 Mn |
| Jun 30, 2021 | 210.31 Mn |